Voxelotor as a Treatment of Persistent Hypoxia in the ICU.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 37423700.
- Also identified by DOI 10.1016/j.chest.2023.01.036.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hypoxia is encountered frequently in the ICU as a result of a wide range of pathologic characteristics. The oxygen-hemoglobin dissociation curve describes hemoglobin's affinity for a given Po<sub>2</sub> and factors affecting uptake and offload. Research in manipulating this relationship between hemoglobin and oxygen is sparing. Voxelotor is a hemoglobin oxygen-affinity modulator that is approved by the US Food and Drug Association for use in the management of sickle cell disease. We present two patients without sickle cell disease who underwent treatment with this novel agent to assist with chronic hypoxia and weaning of mechanical support.
Medical subject headings
- Hemoglobins
- Anemia, Sickle Cell